ProCE Banner Activity

BTK Inhibitor Therapies in CLL/SLL and MCL

Slideset Download
Download this slideset reviewing approved and emerging strategies in treating patients with CLL and MCL with BTK inhibitors.

Released: March 11, 2022

Expiration: March 10, 2023

No longer available for credit.

Share

Faculty

Matthew S. Davids

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Adaptive, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono, Pharmacyclics, Takeda, TG Therapeutics, Verastem, and Zentalis and funds for research support from Ascentage, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Lilly, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, Lilly, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Lilly, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, Lilly, and TG Therapeutics.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo, Nurix, Genmab, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Nurix, Genmab, Loxo, Genentech, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.